Is cognitive reserve a buzzword lacking scientific value?
Host: Robert Perneczky, Germany
Yes:Panteleimon Giannakopoulos, Switzerland
No: Irena Rektorova, Czech Republic
The development in understanding AD has not made an impact on patient care.
Host: Ruth Itzhaki, UK
Yes: Judith Aharon, Israel
No: Sagrario Manzano, Spain
Can AD ever be cured (beyond prevention of progression)?
Host: Nick Fox, UK
No: Martin Rossor, UK
Is subjective cognitive impairment itself a prelude to dementia?
Host: Sagrario Manzano, Spain
Yes: Babak Tousi, USA
No: Panteleimon Giannakopoulos, Switzerland
Is deafness a causative risk factor to dementia?
Host: Gill Livingston, UK
Yes: Sergi Costafreda, UK
Aerobic exercise protects cognition
Host: Miia Kivipelto, Sweden/UK
Yes: Catherine Robb, UK
No: Naji Tabet, UK
Is the new NIA-AA research definition of AD helpful?
Host: Edson Amaro, Brazil
Yes: Paul Edison, UK
Will big data help us to find cure for dementia?
The term Frontotemporal Dementia (FTD) is no longer of value
Host:Janine Diehl-Schmid, Germany
All patients with a diagnosis of FTD should have genetic testing
Host:John Hardy, UK
Yes:Lea Grinberg, Brazil/USA
DEMENTIA SATELLITE – OVERCOMING THE IMPASSE IN DEMENTIA PREVENTION
The complex reality Amos Korczyn, Israel
Epidemiology: is the frequency of dementia changing and why? Are time trends in AD similar to those seen in other related disorders such as stroke or FTD? TBD
Are environmental interventions (optimal CV control, diet, physical activity, etc.) likely to change the frequency and by how much? Kristine Yaffe, UK
What can pathology contribute to our understanding, given that autopsies come very late in the disease course and show mixed pathology in most cases? Lea Grinberg, Brazil/USA
Are amyloid and tau dead horses in sporadic, late onset AD, given the disappointments with interventions that were successful in eliminating amyloid yet without clinical benefit? David Knopman, USA
How can we improve our animal models which so far have been based primarily on transgenic animals with mutations coming from early onset genetic cases, while late onset sporadic disease is associated with completely different factors? TBD
Is APOE4 a potential treatment target, given that we do not understand its mechanism? Daniel Michaelson, Israel
Is neuroinflammation: a useful potential therapeutic target? Michael Heneka, Germany
How should we allocate resources, given that until now 90% were allocated to amyloid and tau research which has led us nowhere? TBD
The need for multiple targets, outcomes, and approaches Vladimir Hachinski, Canada